As originally reported in European Pharmaceutical Manufacturer Magazine, Chiesi, an Italian pharmaceutical company, has announced they will be launching a new division for rare disease research and therapy innovation. The headquarters for ‘Chiesi Global Rare Diseases’ will be located in Boston, Massachusetts, joining the many facilities the Italian manufacturer has scattered across the world. Chiesi has already made inroads into the arena of rare disease treatment when they acquired the rights to commercialize an enzyme replacement therapy for Fabry disease in 2016. This inspired further dedication of their resources and energy to researching and developing medications focused on rare diseases that include lysosomal storage disorders, rare hematology, and ophthalmology.
The company’s product Lamzede already approved to treat the rare disease alpha-mannosidosis. The head of the new rare disease division, Giacomo Chiesi, says
“Chiesi has a long history of success in discovering, developing and commercializing innovative therapies to address unmet needs for people living with rare diseases. With the Chiesi Global Rare Diseases unit, we are taking this to an entirely new level – rededicating and strengthening our efforts to support individuals and families affected by rare diseases all around the world.”
